Anti-osteoporosis agent-8
Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3036050-96-8
- Formule: C18H19F3N2O2Se
- Masse moléculaire:431.31
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMMC | IC50 |
2.41 μM
Compound: 4aa
|
Anti-osteoclastogenesis activity in M-CSF/RANKL-induced C57BL/6 mouse BMMC cells assessed as inhibition of osteoclasts formation incubated for 6 days with media replacement for every 2 days by TRAP-staining based light microscopic analysis
Anti-osteoclastogenesis activity in M-CSF/RANKL-induced C57BL/6 mouse BMMC cells assessed as inhibition of osteoclasts formation incubated for 6 days with media replacement for every 2 days by TRAP-staining based light microscopic analysis
|
[PMID: 38630440] |
In Vitro
Anti-osteoporosis agent-8 (0-10 μM, 5 days) promotes osteoblast differentiation in cells MC3T3-E1 through activation of BMP2 signaling pathway[1].
Anti-osteoporosis agent-8 (5 μM, 6 h) inhibits the osteoclast-related genes expression, osteoclastogenesis, and osteoclastic bone resorption, though inhibition of MAPK and NF-κB-signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ovariectomized C57BL/6 mice model[1]
-
Dosage:10 mg/kg
-
Administration:i.p., every other days, for 8 weeks
-
Result:Reduced the bone loss, increased bone volume/total bone volume, trabecular thickness and trabecular number, without significant toxicity in mainly organs.
Chemical Information
-
CAS No. 3036050-96-8
-
Masse moléculaire 431.31
-
Formule C18H19F3N2O2Se
-
SMILES
O=C(NC1=CC=NC=C1)C([Se]C2=CC=CC=C2)C(C)(OCC(F)(F)F)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-osteoporosis agent-8 Related Classifications
HY-158311 Related Classifications
Powered by Bioz